Core Viewpoint - The approval of the new indication for Pyrotinib (brand name: XuanYueNing) for first-line treatment of HR+/HER2- advanced breast cancer significantly enhances its clinical value and accessibility, supporting future sales growth for the company [1]. Company Summary - Four Seasons Pharmaceutical (00460) announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1]. - This marks the third approved indication for Pyrotinib in China, making it the first and only drug in the country to cover the entire treatment course for HR+/HER2- advanced breast cancer across first, second, and later lines [1]. Industry Summary - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of total cases, with about 30% of these patients diagnosed with advanced breast cancer [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer in China is expected to reach RMB 13 billion by 2032 [2]. Clinical Research Summary - The approval of the new indication is based on data from the BRIGHT-3 study (NCT05257395), a randomized, double-blind Phase III clinical trial conducted at 58 centers in China [3]. - The study aimed to evaluate the efficacy and safety of Pyrotinib in combination with Letrozole or Anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [3]. - Results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, while the control group reported mPFS of 18.43 months and 19.55 months, suggesting a durable efficacy advantage for Pyrotinib [3]. - The Pyrotinib regimen reduced the risk of disease progression or death by 47% compared to the placebo combined with endocrine therapy, with a notable 64% reduction in patients with liver metastases [3]. - The overall response rate (ORR) in the intention-to-treat population for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [3]. - Common adverse events associated with the Pyrotinib regimen were mostly grade 1-2 and manageable through supportive care or dose adjustments, indicating an overall controllable safety profile [3].

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在2025年欧洲肿瘤内科学会 (2025年ESMO)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估的mPFS 均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患者仍未发 生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低47%的疾 病进展或死亡风险，且尤其在预后较差的肝转移患者中，疾病进展或死亡风险大幅降低64%，显示出其 在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组的42.5%; 安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通过支持治 疗或剂量调整得以有效管理，整体安全性可控。 乳腺癌是全球女性最常见被诊断出的恶性肿瘤，灼识咨询报告显示，中国 ...

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在二零二五年欧洲肿瘤内科学 会(「2025年ESMO」)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估 的mPFS均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患 者仍未发生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低 47%的疾病进展或死亡风险，且尤其在预後较差的肝转移患者中，疾病进展或死亡风险大幅降低64%， 显示出其在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组 的42.5%；安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通 过支持治疗或剂量调整得以有效管理，整体安全性可控。 相关事件 四环医药(00460.HK)：轩悦宁®(吡洛西利片 ...

本次新适应症的获批主要基于BRIGHT-3研究(NCT05257395)的数据结果。BRIGHT-3研究是一项在中国 58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗 HR+/HER2-晚期乳腺癌的有效性和安全性。此前，BRIGHT-3的研究成果在2025年欧洲肿瘤内科学会 (2025年ESMO)首次发表。结果显示，在疗效方面，吡洛西利组由研究者和独立评审委员会评估的mPFS 均暂未达到，对照组分别为18.43个月和19.55个月。mPFS尚未达到，提示吡洛西利组有更多患者仍未发 生疾病进展，反映出其持久的疗效优势。与安慰剂联合内分泌治疗相比，吡洛西利方案可降低47%的疾 病进展或死亡风险，且尤其在预后较差的肝转移患者中，疾病进展或死亡风险大幅降低64%，显示出其 在难治人群中的突出潜力。在意向治疗人群中，吡洛西利组的ORR达63.5%，显著优于对照组的42.5%; 安全性方面，吡洛西利联合方案常见不良事件(如腹泻、中性粒细胞减少等)多为1–2级，可通过支持治 疗或剂量调整得以有效管理，整体安全性可控。 四环医药(00460)发布公告，集团旗下非全资附属公司轩竹生物科 ...

乳腺癌是全球女性最常见被诊断出的恶性肿瘤，灼识谘询报告显示，中国乳腺癌新发病例由二零一八年 的322,200例增至二零二四年的374,700例，预计二零三二年将达到435,000例。HR+/HER2-乳腺癌是中国 最高发的亚型，占病例总数约75%，HR+/HER2-乳腺癌患者中约有30%被诊断为晚期乳腺癌。在中国， CDK4/6抑制剂联合内分泌治疗用于HR+/HER2-晚期乳腺癌已成为标准一线治疗，中国CDK4/6抑制剂市 场规模预计二零三二年将达至人民币130亿元。 格隆汇3月3日丨四环医药(00460.HK)宣布，集团旗下非全资附属公司轩竹生物科技股份有限公司("轩竹 生物")自主研发的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂("AI")一线治疗激素受体阳 性(HR+)、人表皮生长因子受体2阴性(HER2-)("HR+/HER2-")晚期乳腺癌的新适应症上市申请 ("sNDA")，已获得中国国家药品监督管理局(「NMPA」)批准上市。这是吡洛西利继联合氟维司群、单 药治疗适应症获批后，在中国获批的第三个适应症，至此吡洛西利成为中国首个且唯一覆盖 HR+/HER2-晚期乳腺癌一线、二线、后线全 ...

Core Viewpoint - The company has entered into a collaboration agreement with Aohong Pharmaceutical for exclusive commercialization rights of a product in the field of HR+ and HER2– breast cancer treatment, enhancing its pipeline and revenue potential [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025 [1] - Aohong Pharmaceutical grants the company exclusive rights for the commercialization of the product within a specified region and field [1] - The memorandum of understanding has been replaced by the collaboration agreement and will automatically terminate on December 3, 2025 [1] Group 2: Product Details - The licensed product, citric acid voraselis capsule, is a CDK4/6 inhibitor approved for the treatment of HR+ and HER2– breast cancer [1] - The product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergy with existing breast cancer pipeline products [1] - Introducing this licensed product will enrich the company's pipeline and leverage its existing breast cancer commercialization team and resources to enhance future revenue scale [1]

Core Viewpoint - Xuan Bamboo Biotech-B (02575) presented interim analysis results of the BRIGHT-3 clinical trial at the 2025 European Society for Medical Oncology (ESMO), demonstrating the efficacy and safety of Pyrotinib combined with Letrozole or Anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [1][2]. Group 1: Clinical Trial Details - The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted at 58 centers in China, involving 397 HR+/HER2- advanced breast cancer patients [1]. - Among the intention-to-treat population, 55.7% of patients had visceral metastases, and 41.3% were newly diagnosed with advanced disease [1]. Group 2: Efficacy Results - The median follow-up time was 20.7 months as of January 10, 2025, with the mPFS for the Pyrotinib group not yet reached, while the control group reported mPFS of 18.43 months and 19.55 months [2]. - The Pyrotinib regimen reduced the risk of disease progression or death by 47% compared to the placebo combined with endocrine therapy, with a notable 64% risk reduction in patients with liver metastases [2]. - The overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5% [2]. Group 3: Safety Profile - Common adverse events associated with the Pyrotinib combination therapy were mostly grade 1-2, including diarrhea and neutropenia, which can be effectively managed through supportive care or dose adjustments [2]. - The overall safety profile of the Pyrotinib regimen is considered manageable [2]. Group 4: Regulatory Approval - Based on the interim data from the BRIGHT-3 study, the National Medical Products Administration of China accepted the new drug application for Pyrotinib combined with aromatase inhibitors for HR+/HER2- advanced breast cancer on May 14, 2025 [2]. Group 5: Product Information - Pyrotinib (brand name: XuanYueNing) is a novel CDK2/4/6 inhibitor with a unique multi-target synergistic mechanism, effectively inhibiting tumor cell proliferation while significantly reducing hematological toxicity compared to traditional CDK4/6 inhibitors [3]. - On May 13, 2025, Pyrotinib was approved for use in combination with Fulvestrant for patients who progressed after prior endocrine therapy, and as a monotherapy for patients who had previously received two or more endocrine therapies and one chemotherapy [3].

Core Insights - The 2025 European Society for Medical Oncology (ESMO) annual meeting will take place in Germany from October 17 to 21, where several significant oral reports from domestic innovative pharmaceutical companies are expected to be disclosed [1] - China National Pharmaceutical Group is set to present key data on its CDK2/4/6 inhibitor, Kumosili, and HER2 dual-target ADC, TQB2102, highlighting its comprehensive coverage in the breast cancer treatment landscape [1] Industry Overview - Breast cancer is the second most common cancer globally, following lung cancer, and has the highest incidence and mortality rates among women [1] - The breast cancer market is highly competitive, particularly in the HR+/HER2- subtype, which accounts for approximately 65%-70% of all breast cancer cases [2] - The global market for CDK4/6 inhibitors is projected to approach $13 billion by 2024, with ongoing growth driven by products from Pfizer, Eli Lilly, and Novartis [2] Company Developments - Kumosili capsules, a new generation CDK2/4/6 inhibitor, are expected to receive approval for second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer by the end of this year [3] - The company is also advancing its clinical trials for Kumosili in first-line and adjuvant settings, aiming for comprehensive coverage across treatment lines [3] - TQB2102, another product from China National Pharmaceutical Group, will present phase Ib clinical data for HER2-positive recurrent/metastatic breast cancer at ESMO [3] Competitive Landscape - The ADC market for HER2-positive breast cancer is evolving, with significant sales from existing products like DS-8201, which reached $3.8 billion last year and is projected to peak at $10 billion [4] - TQB2102 has been optimized in terms of target binding, toxin load, and payload compared to DS-8201, and has been recognized as a breakthrough therapy for multiple indications [4] - The company has a diverse pipeline covering various cancer types, including breast, colorectal, lung, bile duct, and gastric cancers, with several indications entering phase III clinical trials [4]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for its innovative small molecule CDK4/6 inhibitor, Fovisei (Citrus Acid Vovisil Capsules), for a new indication in the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in premenopausal, postmenopausal, and perimenopausal women [1][3]. Group 1 - The approval allows Fovisei to be used in combination with aromatase inhibitors as initial endocrine therapy for specific breast cancer patients [1][3]. - Breast cancer is a significant health threat to women, with approximately 357,200 new cases reported in China in 2022, making it the second most common malignant tumor among women [3]. - CDK4/6 inhibitors are crucial treatment options for HR+/HER2- populations with endocrine resistance [3]. Group 2 - Fovisei is classified as a first-class new drug, characterized as an oral, potent, highly selective, and structurally novel small molecule medication [3]. - The drug can penetrate the blood-brain barrier, providing new treatment opportunities for patients with brain metastases [3]. - Taimei Medical Technology, as a partner, played a key role in the independent imaging assessment for the drug's approval, leveraging its extensive experience and quality management systems [3].

Group 1 - The core point of the news is that Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (brand name: Fuzhuoning) for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] - The newly approved indication allows the drug to be used in combination with aromatase inhibitors as initial endocrine therapy [1] - The drug is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights, classified as a new structure oral medication [1] Group 2 - The drug had previously received approval for another indication for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after prior endocrine therapy, which was approved for market entry in China by May 2025 [1] - As of August 2025, the cumulative R&D investment for this drug is approximately RMB 617 million (unaudited) [1] - According to IQVIA MIDAS™ data, global sales of CDK4/6 inhibitors are projected to be around $14.912 billion in 2024, indicating a strong market potential for the newly approved indication [2]